Literature DB >> 13324088

Acute myeloid leukemia following prolonged iodine-131 therapy for metastatic thyroid carcinoma.

S M SEIDLIN, E SIEGAL, A A YALOW, S MELAMED.   

Abstract

Entities:  

Keywords:  IODINE/radioactive; LEUKEMIA, MYELOCYTIC/etiology and pathogenesis; THYROID GLAND/neoplasms

Mesh：

Substances：

Year:  1956        PMID： 13324088     DOI： 10.1126/science.123.3201.800

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  9 in total

1.  Blood radiation dose after 131-I therapy of thyrotoxicosis. Calculations with reference to leukaemia.

Authors:  M GREEN; M FISHER; H MILLER; G M WILSON
Journal:  Br Med J       Date:  1961-07-22

Review 2.  Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma.

Authors:  Frederik A Verburg; Markus Dietlein; Michael Lassmann; Markus Luster; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

3.  The difference between medicine and magic is that magicians know what they are doing.

Authors:  Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01       Impact factor: 9.236

4.  I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies: an "inconvenient" truth?

Authors:  Frederik A Verburg; Luca Giovanella; Ioannis Iakovou; Mark W Konijnenberg; Werner Langsteger; Michael Lassmann; Jasna Mihailovic; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-08       Impact factor: 9.236

5.  Radioactive Iodine-Related Clonal Hematopoiesis in Thyroid Cancer Is Common and Associated With Decreased Survival.

Authors:  Laura Boucai; John Falcone; Jenny Ukena; Catherine C Coombs; Ahmet Zehir; Ryan Ptashkin; Michael F Berger; Ross L Levine; James A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

6.  Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies.

Authors:  Frederik A Verburg; Martha Hoffmann; Ioannis Iakovou; Mark W Konijnenberg; Jasna Mihailovic; Pablo Minguez Gabina; Petra Petranović Ovčariček; Cristoph Reiners; Alexis Vrachimis; Slimane Zerdoud; Luca Giovanella; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03       Impact factor: 9.236

7.  Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.

Authors:  Remco J Molenaar; Surbhi Sidana; Tomas Radivoyevitch; Anjali S Advani; Aaron T Gerds; Hetty E Carraway; Dana Angelini; Matt Kalaycio; Aziz Nazha; David J Adelstein; Christian Nasr; Jaroslaw P Maciejewski; Navneet S Majhail; Mikkael A Sekeres; Sudipto Mukherjee
Journal:  J Clin Oncol       Date:  2017-12-18       Impact factor: 50.717

Review 8.  Pediatric papillary thyroid cancer: current management challenges.

Authors:  Frederik A Verburg; Hanneke M Van Santen; Markus Luster
Journal:  Onco Targets Ther       Date:  2016-12-28       Impact factor: 4.147

Review 9.  Theranostics in nuclear medicine practice.

Authors:  Anna Yordanova; Elisabeth Eppard; Stefan Kürpig; Ralph A Bundschuh; Stefan Schönberger; Maria Gonzalez-Carmona; Georg Feldmann; Hojjat Ahmadzadehfar; Markus Essler
Journal:  Onco Targets Ther       Date:  2017-10-03       Impact factor: 4.147
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.